NCT04617600 is a NA clinical trial of MTA in Reversible Pulpitis, sponsored by Cairo University.

Who is sponsoring NCT04617600?

NCT04617600 is sponsored by Cairo University.

What drugs are being tested in NCT04617600?

Interventions in NCT04617600: MTA, TheraCal PT.

What condition does NCT04617600 study?

NCT04617600 studies Reversible Pulpitis.

Is NCT04617600 still recruiting?

NCT04617600 is currently status unknown. Last updated 4 March 2022.

Last reviewed 2022-03-04 · How we verify

NCT04617600

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Survival Rate After TheraCal PT Pulpotomy Versus MTA Pulpotomy in Children With Vital Primary Molars.

Status unknown NA Last updated 4 March 2022

What this trial tests

NA trial testing MTA in Reversible Pulpitis in 20 participants. Status unknown.

Timeline

1 March 2022

Primary endpoint
1 June 2022

1 November 2022

Quick facts

Lead sponsor	Cairo University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	20
Start date	1 March 2022
Primary completion	1 June 2022
Estimated completion	1 November 2022

Drugs / interventions tested

MTA — full drug profile →
TheraCal PT — full drug profile →

Conditions studied

Reversible Pulpitis — all drugs for Reversible Pulpitis →

Sponsor

Cairo University

Who can join

Adults 4 to 7, any sex, with Reversible Pulpitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to assess the effect of TheraCal PT pulpotomy versus MTA pulpotomy on the survival rate of cariously exposed vital primary molars.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of MTA

Trials testing the same drug.

NCT06795282 — Post Operative Sensitivity of MTA Obturation · completed
NCT06170775 — Sodiumhexametaphosphate as Pulp Capping Material for Primary Teeth · NA · unknown
NCT06170762 — Sodiumhexametaphosphate Versus MTA as Pulp Capping Material for Immature Permanent Teeth · NA · unknown
NCT05498337 — Vital Pulp Therapy With Different Materials for Young Permanent Teeth · NA · completed
NCT05419752 — Clinical Assessment of 3 Differant Obturation Sealers on Postoprative Pain and Swelling · Phase 2, PHASE3 · unknown

Other recruiting trials for Reversible Pulpitis

Currently open trials in the same condition.

NCT07073573 — Evaluation of Pulpal Biomarkers in Vital Pulp Therapy · NA · active not recruiting
NCT07391124 — In Vivo Pulp Thermal Changes During Different Slenderization Techniques · NA · active not recruiting
NCT06844448 — The Effect of Different Risk Factors on the Success Rate of VPT · recruiting
NCT06433297 — Comparative Evaluation of Indirect vs. Direct Pulp Capping in Deep Carious Mandibular Molars · NA · recruiting
NCT07101068 — Assessment of Pain and Anxiety During Infiltration Anesthesia Using Dental Anesthesia Injector Versus Conventional Syrin · NA · recruiting

Other Cairo University trials

Trials by the same sponsor.

NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04617600 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cairo University
Last refreshed: 4 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04617600.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing